Firms to co-develop heart-failure drug in potential $430M deal

05/10/2013 | American City Business Journals

Trevena and Forest Laboratories entered into a licensing-option deal involving TRV027, Trevena's drug candidate for acute heart failure. Forest agreed to make a $30 million equity stake in Trevena in exchange for an option to license TRV027. If Forest exercises its option, Trevena will be entitled to as much as $430 million in milestone fees plus sales royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA